112 related articles for article (PubMed ID: 3583222)
21. Therapeutic responses to corticosteroids in Graves' ophthalmopathy.
Chang TC; Kao SC; Hsiao YL; Lu CP; Huang KM; Tzeng SS
J Formos Med Assoc; 1996 Nov; 95(11):833-8. PubMed ID: 8990770
[TBL] [Abstract][Full Text] [Related]
22. Carbimazole-Resistant Graves' Disease Responding to Oral Prednisolone: A Case Report.
Kamrul-Hasan AB; Mondal E
Mymensingh Med J; 2022 Apr; 31(2):553-555. PubMed ID: 35383779
[TBL] [Abstract][Full Text] [Related]
23. [Use of plasmapheresis in a case of Graves' disease with malignant ophthalmopathy (author's transl)].
Glinoer D; Gaham N; Sand G; Libert J; Grivegnee A; Badjou R; Ermans AM
Ann Endocrinol (Paris); 1981 Dec; 42(6):545-6. PubMed ID: 6896620
[TBL] [Abstract][Full Text] [Related]
24. T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production.
Lai KN; Leung JC; Chow CC; Cockram CS
Acta Endocrinol (Copenh); 1989 May; 120(5):602-9. PubMed ID: 2786308
[TBL] [Abstract][Full Text] [Related]
25. Graves' disease, endocrine ophthalmopathy and smoking.
Winsa B; Mandahl A; Karlsson FA
Acta Endocrinol (Copenh); 1993 Feb; 128(2):156-60. PubMed ID: 8451910
[TBL] [Abstract][Full Text] [Related]
26. [On the pathogenetic significance of hypophyseal factors in endocrine ophthalmopathy].
Mertz DP; Stelzer M
Dtsch Med Wochenschr; 1969 Jan; 94(1):27-32. PubMed ID: 5818126
[No Abstract] [Full Text] [Related]
27. [Inactive Graves' ophthalmopathy and self-esteem].
Magalhães CH; Pereira MD; Manso PG; Veiga DF; Novo NF; Ferreira LM
Arq Bras Oftalmol; 2008; 71(2):215-20. PubMed ID: 18516421
[TBL] [Abstract][Full Text] [Related]
28. Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Van der Gaag R; Mourits MP; Koornneef L
Clin Exp Immunol; 1992 Jun; 88(3):405-9. PubMed ID: 1606722
[TBL] [Abstract][Full Text] [Related]
29. Endocrine ophthalmopathy in a patient under continuous immunosuppressive therapy after cardiac transplantation.
Höfle G; Moncayo R; Baldissera I; Pfister R; Finkenstedt G
Thyroid; 1995 Dec; 5(6):477-80. PubMed ID: 8808100
[TBL] [Abstract][Full Text] [Related]
30. Correlation of plasma free thyroxine levels with insulin sensitivity and metabolic clearance rate of insulin in patients with hyperthyroid Graves' disease.
Ohguni S; Notsu K; Kato Y
Intern Med; 1995 May; 34(5):339-41. PubMed ID: 7647398
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy.
Kahaly G; Pitz S; Müller-Forell W; Hommel G
Clin Exp Immunol; 1996 Nov; 106(2):197-202. PubMed ID: 8918563
[TBL] [Abstract][Full Text] [Related]
32. Pterional orbital decompression in progressive ophthalmopathy of Graves' disease. I. Short-term effects.
Algvere P; Almqvist S; Backlund EO
Acta Ophthalmol (Copenh); 1973; 51(4):461-74. PubMed ID: 4128795
[No Abstract] [Full Text] [Related]
33. Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives.
Legler UF; Benet LZ
Clin Pharmacol Ther; 1986 Apr; 39(4):425-9. PubMed ID: 3956058
[TBL] [Abstract][Full Text] [Related]
34. Effect of octreotide treatment on Graves' ophthalmopathy.
Uysal AR; Corapçioğlu D; Tonyukuk VC; Güllü S; Sav H; Kamel N; Erdoğan G
Endocr J; 1999 Aug; 46(4):573-7. PubMed ID: 10580750
[TBL] [Abstract][Full Text] [Related]
35. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy.
Marinó M; Morabito E; Brunetto MR; Bartalena L; Pinchera A; Marocci C
Thyroid; 2004 May; 14(5):403-6. PubMed ID: 15186621
[No Abstract] [Full Text] [Related]
36. [The effects of intensive DMPA regimen in the treatment of Graves' ophthalmopathy].
Wei S; Tong N; Luo Q; Tian H; Yu Y; Liu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1996 Sep; 27(3):306-9. PubMed ID: 9389069
[TBL] [Abstract][Full Text] [Related]
37. The permeability of the corneal epithelium of Graves' ophthalmopathy as determined by fluorophotometry.
Khalil HA; van Best JA; de Keizer RJ
Doc Ophthalmol; 1989 Nov; 73(3):249-54. PubMed ID: 2638243
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Graves' ophthalmopathy with cyclosporin A.
Kvetny J; Frandsen NE; Johnsen T; Dieperinck H; Mogensen E
Acta Med Scand; 1986; 220(2):189-91. PubMed ID: 3535393
[TBL] [Abstract][Full Text] [Related]
39. [Step-by-step treatment of progressive edematous-infiltrative ophthalmopathy in Graves' disease. Results of the first stage of treatment with glucocorticoids and glucocorticoids with azathioprine].
Pilarska K; Czekalski S; Syrenicz A; Andrzejewska W; Krzystolik Z; Przerwa D; Daniel B
Endokrynol Pol; 1988; 39(5):229-36. PubMed ID: 3076562
[No Abstract] [Full Text] [Related]
40. [An integrated approach to the treatment of pretibial myxedema based on pulse therapy with prednisolone and electrical neuromyostimulation (FREMS-therapy) in a patient with Graves' disease and thyroid eye disease].
Perepelova MA; Zaitseva EL; Bessmertnaya EG; Grusha YO; Sviridenko NY; Galstyan GR
Probl Endokrinol (Mosk); 2023 Aug; 69(4):32-37. PubMed ID: 37694865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
